NL-OMON38390
Completed
Phase 2
Can HDL Infusions Significantly Quicken Atherosclerosis Regression? A phase II, Multi-center, double-blind, ascending dose, placebo-controlled, dose-finding trial of CER-001 or placebo in subjects with acute coronary syndrome. - CHI SQUARE
Cerenis Therapeutics SA0 sites80 target enrollmentTBD
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Acute Coronary Syndrome
- Sponsor
- Cerenis Therapeutics SA
- Enrollment
- 80
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •male or female up to and including 80 years of age, acute chest pain and diagnosis of ST segment elevation or non\-ST elevation myocadial infarction or unstable angina, clincally indicated coranary angiography, evidence of coronary artery disease, and an appropriate target coronary artery.
Exclusion Criteria
- •Subjects weighing more than 160 kg, uncontrolled diabetes, triglycerides greater than 500 mg/dl, baseline ivus of unacceptable quality, subjects for whom CABG is planned, hemodynamically or clinically unstable, and ejcection fraction less than 35%.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Not Applicable
High HDL cholesterol and ASCVD risk scoreHealth Condition 1: E789- Disorder of lipoprotein metabolism, unspecifiedHealth Condition 2: E789- Disorder of lipoprotein metabolism, unspecifiedCTRI/2019/12/022320Kasturba Medical College
Completed
Phase 3
High-Density Lipoprotein (HDL) Modulation and Endothelial FunctionAtherosclerosisNCT00150722University of Calgary75
Completed
Not Applicable
Anti-atherosclerosis effects of 12 weeks high intensity interval and aerobic training on serum levels salusin-a and -ß, nitric oxide, inflammatory markers and lipid profile in overweight and obese childrensAnti-Atherosclerosis Effects of exercise.IRCT20200116046154N1Razi University45
Recruiting
Phase 4
Effect of Intensive LDL-cholesterol Targeting for Elderly Patients With Cardiovascular Disease: I-OLD TrialCardiovascular DiseaseNCT05361421Yonsei University1,200
Completed
Not Applicable
Improving Metabolism With HDL CholesterolHeart DiseaseDiabetesNCT00395148Bayside Health13